Pancreatic Cancer Research

ResearcherSanford Burnham Prebys Medical Discovery InstituteActive in the last 2 years

Hervé Tiriac

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5039-6750; OpenAlex author ID A5013005773. Sources: OpenAlex.

Their work

Papers
45 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
195
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 4 papers · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers · 2026: 9 papers

Papers 45

  1. Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". Co-author DOI 10.1016/j.jpet.2026.104305↗
  2. ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. Co-author DOI 10.1038/s41589-025-01978-1↗
  3. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
  4. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Co-author DOI 10.1073/pnas.2511733123↗
  5. Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy. Co-author DOI 10.1158/0008-5472.can-25-5676↗
  6. The Times They Are A-Changin': Pancreatic Cancer Surgery in the RAS Inhibitor Era. Co-author DOI 10.1245/s10434-026-20525-3↗
  7. CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation Co-author DOI 10.64898/2026.04.08.717301↗
  8. Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment Co-author DOI 10.64898/2026.04.14.718544↗
  9. CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.22.727290↗
  10. Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jpet.2025.103573↗
  11. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  12. Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer Co-author DOI 10.1101/2025.05.29.656904↗
  13. MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/0008-5472.can-24-0744↗
  14. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  15. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-023-00649-1↗
  16. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. Co-author DOI 10.1172/jci.insight.172419↗
  17. Pancreatic ductal adenocarcinoma induces neural injury that promotes a transcriptomic and functional repair signature by peripheral neuroglia. Co-author DOI 10.1038/s41388-023-02775-7↗
  18. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  19. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
  20. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metasta… Co-author DOI 10.1136/jitc-2022-006133↗
  21. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-23-1313↗
  22. Lead identification using 3D models of pancreatic cancer. Co-author DOI 10.1016/j.slasd.2022.03.002↗
  23. Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. Co-author DOI 10.1016/j.cgh.2020.02.045↗
  24. The autophagy initiating kinase ULK1 is required for pancreatic cancer cell growth and survival Co-author DOI 10.1101/2021.05.15.444304↗
  25. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3210↗
  26. Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. First author DOI 10.3390/cancers13194991↗
  27. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  28. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  29. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  30. Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models. Co-author DOI 10.3791/60364↗
  31. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. First author DOI 10.1007/978-1-4939-8879-2_9↗
  32. Organoid models for translational pancreatic cancer research. Co-author DOI 10.1016/j.gde.2019.02.003↗
  33. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. First author DOI 10.1126/science.aaw3145↗
  34. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  35. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.celrep.2018.10.051↗
  36. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Co-author DOI 10.1016/j.gie.2017.12.032↗
  37. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  38. Dynamic changes during the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24483↗
  39. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.cell.2017.07.007↗
  40. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  41. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  42. Modeling pancreatic cancer with organoids. First author DOI 10.1016/j.trecan.2016.03.004↗
  43. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Co-author DOI 10.18632/oncotarget.9551↗
  44. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  45. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗

Closest collaborators

The 25 strongest of 195 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew M. Lowy · 19 shared papers, 2020–2026 · strength 4.14
  2. Dannielle D. Engle · 16 shared papers, 2014–2026 · strength 2.52
  3. David Arthur Tuveson · 20 shared papers, 2014–2024 · strength 1.62
  4. Jonathan Weitz · 7 shared papers, 2021–2026 · strength 1.51
  5. Satoshi Ogawa · 4 shared papers, 2023–2026 · strength 0.84
  6. Ronald M. Evans · 6 shared papers, 2014–2026 · strength 0.82
  7. Kevin Christian Montecillo Gulay · 4 shared papers, 2023–2026 · strength 0.76
  8. Casie S. Kubota · 3 shared papers, 2026 · strength 0.68
  9. Jan C. Lumibao · 4 shared papers, 2021–2026 · strength 0.64
  10. Lindsey A. Baker · 7 shared papers, 2015–2020 · strength 0.62
  11. Bharti Garg · 3 shared papers, 2023–2025 · strength 0.56
  12. Youngkyu Park · 8 shared papers, 2015–2024 · strength 0.55
  13. Paul A. Insel · 2 shared papers, 2025–2026 · strength 0.49
  14. Elena Tomás Bort · 2 shared papers, 2025–2026 · strength 0.49
  15. Peter James McCormick · 2 shared papers, 2025–2026 · strength 0.49
  16. Krishna Sriram · 2 shared papers, 2025–2026 · strength 0.49
  17. Richard Philip Grose · 2 shared papers, 2025–2026 · strength 0.49
  18. Cristina Salmerón · 2 shared papers, 2025–2026 · strength 0.49
  19. Michael Anthony Hollingsworth · 4 shared papers, 2017–2025 · strength 0.45
  20. Chang‐Il Hwang · 6 shared papers, 2015–2024 · strength 0.44
  21. Christian M. Metallo · 2 shared papers, 2025–2026 · strength 0.43
  22. Jasper Hsu · 2 shared papers, 2026 · strength 0.42
  23. Hyemin Song · 2 shared papers, 2026 · strength 0.42
  24. Steve Gallinger · 4 shared papers, 2020–2025 · strength 0.39
  25. Jean L. Grem · 3 shared papers, 2017–2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.